Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) today announced its participation at the 19th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), taking place 3-6 February 2026 in Dublin, Ireland. At this year’s meeting, Sobi will present new haemophilia data with seven scientific abstracts, including one oral presentation highlighting three years of treatment with Altuvoct from the XTEND-ed study.
These presentations underscore Sobi’s mission to deliver life-changing therapies for patients with rare and severe blood disorders.
“At EAHAD 2026, we will share long-term data from the XTEND-ed study of Altuvoct prophylaxis in haemophilia A. After three years of treatment, Altuvoct continues to offer protection to these patients, confirming the original registrational data. The few bleeds were managed well, and the data showed no unexpected safety issues. This underscores our belief in the potential of Altuvoct,” said Lydia Abad-Franch, MD, Head of R&D and Medical Affairs, and Chief Medical Officer at Sobi. “Haemophilia is a very severe chronic disease. We are committed to advancing the science for people living with this condition.”
Summary of full Sobi data to be presented at EAHAD 2026:
|
Efanesoctocog alfa |
|
|
Efanesoctocog Alfa Prophylaxis for People |
Oral Presentation Session Name: Session 10 – Late Date: 6 February 2026 Presentation Time: 2:30 – 2:45 PM GMT Publication Number: OR17 |
|
Physical Activity and Efficacy in Patients with Severe |
Poster Presentation |
|
Long-Term Clinical Outcomes of Efanesoctocog Alfa |
Poster Presentation |
|
Treatment of Bleeding Episodes with Efanesoctocog |
Poster Presentation |
|
Haemophilia A |
|
|
Assessment of joint health and patient-physician |
Poster Presentation |
|
Clinical, Psychosocial, Quality of Life Outcomes and |
Poster Presentation |
|
rFIXFc |
|
|
Real-World Effectiveness and Usage of rFIXFc in |
Poster Presentation |
Read Also: Nexus Agriscience Subsidiary Terpene Belt Farms Selected for UCLA-Led
